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Abstract: Heart failure is one of the most common, costly, disabling and deadly diseases. During the last decade, several 
different indices reflecting renal function such as creatinine-based glomerular filtration rate, circulating levels of cystatin
C and low-grade albuminuria have been demonstrated to be independent risk factors for heart failure. This review 
summarizes our current knowledge of the relationship between diminished renal function and the incidence of heart 
failure in the community, and also in individuals with increased risk of heart failure such as patients with overt 
cardiovascular disease, hypertension or diabetes. This review will also put forward important areas of future research in 
this field. 
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INTRODUCTION 
  There is growing recognition of the clinical importance 
of the symbiotic relationship between the kidney and the 
heart (Fig. 1) [1]. It is well known that patients with heart 
failure often also develop renal failure, and renal impairment 
in heart failure patients has become increasingly recognized 
as an independent risk factor for morbidity and mortality [2-
9]. A recent meta-analyses by Smith and co-workers [10] 
showed that a large proportion of heart failure patients had 
renal impairment of some degree, and that these patients had 
a 50% increased relative risk for mortality compared to heart 
failure patients with normal renal function. Moreover, almost 
a third of heart failure patients had moderate to severe renal 
impairment, with a more than 2-fold increased relative 
mortality risk and greater than 50% mortality during five 
years of follow-up.  
  The temporal relationship between heart failure and renal 
failure appears to be complex, however, and the opposite 
chain of events is also common: patients with chronic kidney 
disease are at substantially higher risk of developing 
cardiovascular disease and heart failure. In fact, heart failure 
is about 15 times more common in patients with chronic 
kidney disease than in patients with normal renal function 
[11] and individuals with chronic kidney disease are more 
likely to die of cardiovascular disease than to develop end-
stage renal disease [12, 13]. 
  Although the close relationship between cardiovascular 
and renal pathologies is well recognized in advanced 
nephropathy and heart failure, it has received less attention 
in early disease. To date, several studies have suggested that 
diminished renal function may be involved in the deve-
lopment of heart failure at an early stage, prior to the 
development of clinically overt heart failure and kidney 
disease. The present review will focus on studies that have  
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reported the longitudinal relationship between different 
indices of renal function (serum creatinine, creatinine-based 
equations of glomerular filtration rate, serum cystatin C, and 
albuminuria) and the development of heart failure in 
individuals without heart failure at baseline. 
SERUM CREATININE AND CREATININE-BASED 
EQUATIONS OF GLOMERULAR FILTRATION 
RATE AS RISK FACTORS FOR INCIDENCE OF 
HEART FAILURE 
  The serum levels of creatinine and creatinine-based 
equations of glomerular filtration rate have been used exten-
sively in clinical practice, as well as in research, as indirect 
estimates of glomerular filtration rate. Although widely used, 
creatinine-based equations of glomerular filtration rate such 
as Cockroft-Gault [14] or the Modification of Diet in Renal 
Disease (MDRD) equation [15] have been shown to have 
limitations as estimates of glomerular filtration rate, parti-
cularly in the elderly and in individuals with glomerular 
filtration rate in the normal or near-normal range [16]. 
Community-Based Studies 
  The association between elevated serum levels of 
creatinine and the incidence of heart failure in the com-
munity was first reported by Gottdiener and co-workers in 
the Cardiovascular Health Study [17]. In that investigation in 
an elderly study population, a comprehensive evaluation of 
different risk factors for heart failure was performed and 
serum levels of creatinine were suggested to contribute to 
6% of the attributable risk of heart failure [17]. In a more 
recent report from the Cardiovascular Health Study, Fried 
and colleagues concluded that even in a sub-sample of 
healthy individuals and individuals with mild renal 
impairment (defined as serum creatinine >1.5 mg/dL), 
elevated serum creatinine was associated with an increased 
risk of heart failure [18]. The association between creatinine-
based glomerular filtration rate and incidence of heart failure 
has since been validated in another cohort of elderly (the 
EPESE-study) [19] as well as in a cohort with a wider age 
range (the ARIC study)[20]. 224 Current Cardiology Reviews, 2009, Vol. 5, No. 3 Johan Ärnlöv 
High-Risk Populations 
  Serum creatinine levels as a predictor of heart failure has 
also been evaluated in individuals with high risk of heart 
failure such as patients with prevalent cardiovascu- 
lar disease, hypertension, and/or diabetes. In most of these 
studies [21-23], however, heart failure has not been 
evaluated as the primary outcome. For instance, in secondary 
analyses of the Heart Outcomes and Prevention Evaluation 
(HOPE) study, mild renal insufficiency was associated with 
a doubled risk of heart failure in crude analyses but not after 
adjusting for other cardiovascular risk factors [21]. In the 
Valsartan in Acute Myocardial Infarction Trial (VALIANT) 
involving patients with an acute myocardial infarction[22], 
lower glomerular filtration rate (MDRD) was associated with 
a higher risk of heart failure in crude analyses. No multi-
variable analyses were presented in that study. Moreover, a 
comparison of the predictive value of two different 
creatinine-based equations for glomerular filtration rate 
(Cockroft-Gault and MDRD) was performed in the Valsartan 
Antihypertensive Long-term Use Evaluation (VALUE) trial. 
Interestingly, in that study estimated glomerular filtration 
rate according to MDRD was a strong predictor of future 
heart failure events while estimated creatinine clearance 
from Cockroft-Gault was not [23]. 
  In a report from the Heart and Estrogen/Progestin 
Replacement Study (HERS), the primary aim was to identify 
predictors of heart failure in post-menopausal women with 
coronary heart disease [24]. Bibbins-Domingo and co-
workers reported that diabetes was the strongest risk factor 
for heart failure and that diabetic women with depressed 
creatinine clearance were those with the highest risk. The 
relevance of impaired renal function in individuals with 
diabetes is further supported by another study in men and 
women with diabetes, in which those with diabetic 
nephropathy were at increased risk of subsequent heart 
failure [25]. Importantly, in a post-hoc analysis of the 
Reduction of Endpoints in NIDDM with the Angiotensin II 
Antagonist Losartan (RENAAL) trial, patients with diabetes 
and more severe chronic kidney disease had higher incidence 
of heart failure, a trend that was reduced by treatment with 
losartan, an angiotensin receptor blocker [26]. 
CYSTATIN C, A SUPERIOR RISK MARKER FOR 
INCIDENCE OF HEART FAILURE?
  Circulating cystatin C concentration is a relatively novel 
measure of kidney function that has been suggested to over-
come many of the limitations of using creatinine-based 
estimates, as the relationship between kidney function and 
cystatin C concentration does not appear to vary with age, 
sex, and body mass [16, 27, 28]. Recently, cystatin C has 
been suggested to be a more reliable indicator of kidney 
function than creatinine-based glomerular filtration rate, 
particularly in the elderly and in individuals with glomerular 
filtration rate within the normal range [16, 29, 30]. It should, 
however, be noted that the superiority of cystatin C is not 
undisputed, and it is yet to be fully established as the marker 
of choice for glomerular filtration rate in clinical practice 
[31].
Community-Based Studies 
  The association between serum cystatin C and 
development of heart failure in the community was first 
reported by Sarnak and co-workers in the Cardiovascular 
Health Study [32]. Serum cystatin C concentrations were 
associated with a linear increase in risk across quintiles of 
cystatin C, in contrast to serum creatinine concentration or 
estimated GFR where there was a J-shaped association with 
heart failure. This study suggested that serum cystatin C 
concentrations provide a better measure of risk assessment 
than serum creatinine concentrations, particularly in the 
“normal” range of kidney function. This was further 
supported by a subsequent report from the Cardiovascular 
Health Study, where Shlipak and co-workers showed that 
higher serum concentrations of cystatin C independently 
predicted heart failure also in individuals without chronic 
kidney disease while creatinine-based glomerular filtration 
rate equations (MDRD) did not [33].  
  In secondary analyses in the Cardiovascular Health 
study, slightly stronger associations between cystatin C 
levels and heart failure were seen in blacks as compared to 
whites  [32]. The question of ethnic differences in the 
association between renal impairment and the development 
of heart failure was investigated in greater depth by Bibbins-
Domingo in the Health, Aging, and Body Composition Study 
[34]. In that study, the association between renal function 
and heart failure risk was stronger in older black individuals 
than in older white individuals, and this difference was 
particularly evident when cystatin C concentration was used 
to assess renal function. In fact, the population attributable 
risk of heart failure was 47% for blacks with moderate or 
high concentrations of cystatin C but only 5% in whites [34].
  In a recent report from the Physicians’ Health study, 
Djousse and co-workers demonstrated that higher levels of 
cystatin C were associated with an increased risk of heart 
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failure and that this association was evident in hypertensive 
individuals only [35]. This result differs from other 
community-based samples, where no interaction regarding 
hypertensive status has been reported. 
  One major limitation of most studies investigating the 
relationship between renal impairment and incidence of heart 
failure has been the lack of differentiation between systolic 
and diastolic heart failure. This important issue was recently 
addressed by Moran and co-workers in another report from 
the Cardiovascular Health Study [36] In that study, cystatin 
C levels were linearly associated with the incidence of 
systolic heart failure, whereas only the highest concen-
trations of cystatin C were predictive of diastolic heart 
failure [36], suggesting that there may be somewhat different 
pathophysiological pathways leading to these two types of 
heart failure. 
High-Risk Populations 
  Several previous studies have indicated that elevated 
cystatin C levels are predictive of cardiovascular morbidity 
and mortality in patients with prevalent coronary heart 
disease [37, 38], yet the association between cystatin C 
levels and the risk of heart failure in high-risk populations 
has been less studied. In a report from the Heart and Soul 
Study involving ambulatory patients with coronary heart 
disease, higher cystatin C levels were found to predict 
incident heart failure [39]. Interestingly, high cystatin C 
levels had similar predictive value for adverse clinical 
outcomes in individuals with or without microalbuminuria, 
suggesting that the association between higher cystatin C 
concentrations and risk of heart failure is not solely mediated 
by microalbuminuria.  
LOW-GRADE ALBUMINURIA AND THE 
INCIDENCE OF HEART FAILURE 
  Although low-grade albuminuria has traditionally been 
considered to be an indicator of early renal pathology, there 
is an emerging view that albuminuria is also a marker of 
generalized vascular pathology such as endothelial dysfunc-
tion (the STENO hypothesis)[40]. Many prospective studies 
have suggested that increased risk of cardiovascular events 
begins well below the current threshold of microalbuminuria 
[41, 42], yet the association with heart failure has been less 
studied. 
Community-Based Studies 
  There have been a few community-based studies inves-
tigating the relationship between albuminuria and incidence 
of heart failure. In a study by Kistorp and co-workers [43], 
an increased urinary albumin/creatinine ratio was not found 
to be predictive of incidence of heart failure in a Danish 
cohort. It should be noted that in that study, incidence of 
heart failure was considered a secondary endpoint, and there 
was only a low number of heart failure events during follow-
up (n = 19).  
  In contrast, Ingelsson et al. reported that the urinary 
albumin excretion rate predicted heart failure incidence inde-
pendently of both established risk factors for heart failure 
and other indices of renal function (creatinine-based   
glomerular filtration rate (MDRD) and serum cystatin C) in a 
community-based sample of elderly men (the Uppsala 
Longitudinal Study of Adult Men, ULSAM)[44]. Further-
more, urinary albumin excretion rate also remained an inde-
pendent predictor of heart failure incidence in a sub-sample 
without myocardial infarction (either at baseline or during 
follow-up), suggesting that the rate of excretion of urinary 
albumin also predicts the incidence of non-ischemic heart 
failure. 
High-Risk Populations 
  Several authors have reported an association between 
albuminuria and heart failure in patients with diabetes. For 
instance, in the Appropriate Blood Pressure Control   
in Diabetes (ABCD) trial, patients with type 2 diabetes and 
macroalbuminuria were found to have a greater than 
threefold risk of heart failure as compared to diabetics   
with normo- or microalbuminuria [45]. Moreover, in the 
DIABHYCAR study (type 2 DIABetes, Hypertension, 
CArdiovascular Events and Ramipril), every 10-fold inc-
rease in urinary albumin concentration was associated with a 
more than doubled risk [46]. In two reports from the HOPE 
study, in patients either with diabetes or without diabetes, 
microalbuminuria [47] or any degree of albuminuria [42] 
was found to be predictive of heart failure, independently of 
established cardiovascular risk factors (including serum 
creatinine)[42].  
  The predictive importance of low-grade albuminuria in 
hypertensive individuals with left ventricular hypertrophy 
was shown in the LIFE study [48], where a urinary albumin/ 
creatinine ratio of > 3.5 mg/mmol was associated with a 
twofold higher risk of future heart failure. In that study, the 
participants with both albuminuria and ECG strain were at 
particularly high risk. 
  It is important to note that although there are convincing 
data to show that low-grade albuminuria is an independent 
predictor of heart failure, this association should not 
necessarily be construed to imply that there is a direct benefit 
in lowering of the albuminuria level. This essential issue was 
addressed in the landmark study by deZeeuw and co-workers 
in a report from the RENAAL trial. In that study, low-grade 
albuminuria was found to be an independent predictor of 
future heart failure in individuals with diabetic nephropathy, 
but more importantly, a 50% reduction in albuminuria after 6 
months of antihypertensive treatment was associated with a 
27% reduction in heart failure risk, supporting the idea of 
lowering of albuminuria as a treatment goal in order to 
achieve cardiovascular protection [49]. 
THE CONJOINT EFFECT OF GLOMERULAR 
FILTRATION RATE AND ALBUMINURIA FOR THE 
PREDICTION OF HEART FAILURE 
  Even though several previous studies have shown that 
indices of glomerular filtration rate and albuminuria predict 
heart failure independently of each other, the conjoint effect 
of glomerular filtration rate and albuminuria for the predic-
tion of heart failure is less reported. In a secondary analysis 
in the Cholesterol And Recurrent Events (CARE) trial [50], 
myocardial infarction patients with both proteinuria and 
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were more than twice as likely to develop heart failure as 
patients with one abnormality, or with neither.  
FUTURE RESEARCH 
  Despite the relatively large number of studies, several 
important issues regarding the prognostic value of the 
indices of renal dysfunction and the development of heart 
failure remain unresolved. First, there have been no studies 
evaluating whether adding the indices of diminished renal 
function to a model with established risk factors for heart 
failure will improve the model discrimination, calibration, 
and global model fit for the prediction of heart failure [51-
54]. It is essential that this issue be addressed in order for 
these indices to be used in clinical practice, to identify 
individuals who have an elevated risk of heart failure. 
Second, no ideal cut-offs for the indices of renal impairment 
have been identified. The thresholds used have either been 
based on classification of renal disease or on the distribution 
of the variable of interest in a particular sample. Future 
studies must identify relevant thresholds for the different 
renal indices in order to achieve optimal model discrimi-
nation. Thirdly, whether or not the conjoint effect of 
glomerular filtration rate and albuminuria conveys additional 
prognostic information has not been well studied. Fourthly, it 
is important to note that heart failure was not the primary 
outcome in most studies in high-risk populations. Fifth, most 
community-based studies were mainly performed in samples 
taken from the elderly and our knowledge of the predictive 
capacity of the indices of renal function is limited in 
individuals who are less than 65 years old. Sixth, patients 
with renal dysfunction are often excluded from intervention 
trials and our knowledge of whether intervention is 
beneficial in this patient group is limited. There is a need for 
more studies that evaluate the benefit of improvement of 
renal function in lowering the risk of heart failure. Finally, 
there have been few data on the prediction of different 
subtypes of heart failure such as diastolic heart failure and 
non-ischemic heart failure. 
CONCLUSIONS  
  There is a considerable body of data to support the notion 
that diminished renal function, as evaluated by reduced 
glomerular filtration rate or low-grade albuminuria, is an 
independent risk factor for subsequent heart failure both in 
high risk populations such as patients with overt cardio-
vascular disease, hypertension or diabetes, and in the com-
munity. Cystatin C appears to be a superior marker for future 
risk of heart failure compared to serum levels of creatinine or 
creatinine-based equations of glomerular filtration rate. 
Moreover, the risk of heart failure appears to begin at levels 
of glomerular filtration rate and albuminuria that are consi-
dered to be in the normal range according to current clinical 
practice. Some data suggest that the relative importance of 
renal dysfunction for the development of heart failure is 
different in different ethnic groups, an issue that merits 
further studies. Thus, based on the studies presented in this 
review, the close association between renal and cardiac dys-
function already appears to be present before the deve-
lopment of clinically overt renal and cardiovascular disease, 
an observation that challenges the current definition of 
cardiorenal syndrome [1]. 
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